Abcam, ab257633, Human REC8 knockout A549 cell lysate

Size: 1Kit
REC8 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 95 bp deletion in exon6.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 95 bp deletion in exon6.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-REC8, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein REC8 also known as Meiotic Recombination Protein REC8 Homolog plays a mechanical role in the cohesion of sister chromatids during meiosis. This protein weighs approximately 60 kDa and is expressed mostly in germ cells during the prophase of meiosis I. REC8 is structurally related to the cohesin complex family and its primary mechanical function is to maintain the physical connection between sister chromatids ensuring accurate chromosomal segregation during meiosis.
Biological function summary
Sister chromatid cohesion during meiosis depends heavily on REC8 which integrates into the cohesin protein complex. This complex consists of SMC1β SMC3 and STAG3 playing an essential role in meiotic chromosome pairing and segregation. REC8 forms part of this cohesin structure specifically ensuring precise cleavage and separation of chromatids during the anaphase I stage of meiosis which contributes critical fidelity in chromosomal inheritance.
Pathways
REC8 influences the meiotic cell cycle and the associated recombination pathways. These pathways are highly regulated and critical for gametogenesis. Within the meiotic cell cycle pathway REC8 interacts closely with the protein RAD21 which holds key roles across various stages of the cell cycle. The well-orchestrated removal of cohesion by separase enzyme ensures successful homologous chromosome separation highlighting REC8's importance in these cellular processes.
Defects in REC8 function show associations with infertility. Malfunctions in meiotic processes can lead to aneuploidies such as Down syndrome due to improper segregation of chromosomes. At the molecular level mutations or deficiencies in REC8 also connect to cohesinopathies like Cornelia de Lange syndrome where cohesion factor SMC3 could also play a part suggesting shared pathways or compensatory mechanisms related to chromosomal cohesion and segregation during meiosis.